A first-in-class HBO1 inhibitor WM-3835 inhibits castration-resistant prostate cancer cell growth in vitro and in vivo

The prognosis and overall survival of castration-resistant prostate cancer (CRPC) patients are poor. The search for novel and efficient anti-CRPC agents is therefore extremely important. WM-3835 is a cell-permeable, potent and first-in-class HBO1 (KAT7 or MYST2) inhibitor. Here in primary human pros...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi, Yuan-yuan, Ji, Yu, Zhang, Lifeng, Sun, Chuan-yu, Wei, Bing-bing, Yang, Dong-jie, Wan, Hong-yuan, Qi, Xiao-wei, Wu, Sheng, Zhu, Li-jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884225/
https://www.ncbi.nlm.nih.gov/pubmed/36709328
http://dx.doi.org/10.1038/s41419-023-05606-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884225/
https://www.ncbi.nlm.nih.gov/pubmed/36709328
http://dx.doi.org/10.1038/s41419-023-05606-5

Ejemplares similares